Healing Those Who Serve: The Emerging Science of Psilocybin Therapy for Veterans & First Responders

PTSD & Trauma
Written By Bruna Pinheiro

Introduction 

Every year, thousands of veterans and first responders experience trauma-related mental health challenges, including PTSD, treatment-resistant depression, and suicidal ideation, despite traditional therapies and medications. In response, researchers and certified practitioners are exploring psilocybin-assisted therapy (P-AT) as a promising treatment. Growing evidence suggests P-AT may offer transformative benefits for those deeply affected by trauma. 

How Psilocybin Therapy Works 

Psilocybin, the active compound in certain mushrooms, can be administered in two primary contexts: 

  • Medically Supervised Settings: Administered alongside psychological preparation and integration sessions, psilocybin has been shown to reduce activity in the amygdala (a region involved in fear response), enhance emotional empathy, and promote neuroplasticity—the brain’s ability to form healthier neural pathways. 

  • Safe, Supportive Church Settings: Under protections from the Religious Freedom Restoration Act (RFRA), certain legally recognized religious organizations offer psilocybin ceremonies facilitated by certified, trained individuals. These spiritually focused environments emphasize intentionality, community support, and integration practices, providing an alternative path to healing. 

In both settings, the substance temporarily disrupts rigid thought patterns, enabling breakthroughs in entrenched traumatic or depressive belief systems. 

Research on Psilocybin for Veterans & First Responders 

Pilot Study on Treatment-Resistant Depression 

A 2025 study involving 15 U.S. veterans with severe, treatment-resistant depression administered a single 25 mg dose of psilocybin. Results demonstrated significant improvements, with many participants experiencing symptom remission for at least 12 months. 

Proof-of-Concept Trial for Veterans with PTSD 

A pioneering 2023 open-label study protocol was published to investigate psilocybin-assisted therapy specifically targeting PTSD symptoms in veterans, highlighting the therapy’s structured psychological integration. 

Ongoing Clinical Trial (NCT05554094) 

This registered U.S. trial aims to systematically assess the safety and efficacy of P-AT for PTSD among veterans, integrating standardized dosing with psychotherapy. 

Veteran Retreat Observational Study 

Veterans attending psychedelic retreats reported significant reductions in PTSD symptoms, depression, and improvements in overall quality of life, emphasizing the potential of alternative, supportive environments. 

Why Psilocybin May Work for PTSD 

  • Psilocybin temporarily increases neuroplasticity, allowing the brain to restructure trauma-affected neural circuits. 

  • It facilitates mindful insight, emotional processing, and fear extinction, critical components for healing trauma. 

  • When combined with structured integration practices, the therapeutic outcomes can be long-lasting, especially beneficial when traditional treatments have failed. 

Regulatory & Access Landscape 

  • Medical Access: Psilocybin remains federally classified as illegal in the U.S.; however, states like Colorado and Oregon have legalized its therapeutic use under regulated clinical frameworks. 

  • Church-Based Access: Under the Religious Freedom Restoration Act, certain churches legally administer psilocybin sacraments as part of spiritual practice. These environments offer veterans and first responders an accessible and protected setting for healing, supported by trained, certified facilitators. This approach provides vital access for those awaiting broader legalization. 

Internationally, Australia’s Department of Veterans Affairs has begun funding psilocybin therapy under strict clinical guidelines, reflecting increasing acceptance. 

Key Takeaways & Caveats 

  • Promising results in small studies suggest substantial potential for veterans and first responders struggling with PTSD. 

  • Safety and ethical practices must remain paramount, including thorough screening, structured preparation, and supportive integration sessions. 

  • Larger, controlled studies are needed to solidify psilocybin’s therapeutic efficacy specifically for PTSD. 

Conclusion  

Psilocybin-assisted therapy represents a beacon of hope for veterans and first responders facing PTSD. As research continues and legal pathways slowly open, both clinical and protected spiritual settings offer complementary routes to healing. 

References 

Agnorelli, C., Giribaldi, G., & Carhart-Harris, R. (2024). Neuroplasticity and psychedelics: A comprehensive examination of classic compounds in pre-clinical and clinical models. PsyArXiv Preprints. https://arxiv.org/abs/2411.19840 

ClinicalTrials.gov. (2022). Psilocybin-assisted psychotherapy for veterans with PTSD (Clinical trial NCT05554094). U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT05554094 

Davis, A. K., Averill, L. A., Sepeda, N. D., Yehuda, R., & Pietrzak, R. H. (2023). Protocol for an open-label, proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy among veterans with post-traumatic stress disorder. BMJ Open, 13(5), e068884. https://bmjopen.bmj.com/content/13/5/e068884 

Ellis, S., Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2025). Long-term outcomes of single-dose psilocybin for U.S. military veterans with severe treatment-resistant depression. Journal of Affective Disorders, 356, 348–356. https://pubmed.ncbi.nlm.nih.gov/39343309 

Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., & Carhart-Harris, R. L. (2023). Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 80(4), 296–304. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2790020 

Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., & Richards, B. D. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://journals.sagepub.com/doi/full/10.1177/0269881116675513 

National Center for PTSD. (2024). Psychedelic-assisted therapy for PTSD: Treatment essentials. U.S. Department of Veterans Affairs. https://www.ptsd.va.gov/professional/treat/txessentials/psychedelics_assisted_therapy.asp 

Psychedelic treatments for trauma-related disorders. (2024). In Wikipedia. Retrieved May 20, 2024, from https://en.wikipedia.org/wiki/Psychedelic_treatments_for_trauma-related_disorders 

University of Washington Department of Psychiatry and Behavioral Sciences. (2025). Clinical trial to begin enrollment assessing safety of psilocybin for military veterans and first responders with PTSD and alcohol use disorder. https://psychiatry.uw.edu/who-we-are/news-events/news/clinical-trial-to-begin-enrollment-assessing-safety-of-psilocybin-for-military-veterans-and-first-responders 

Bruna Pinheiro
Previous

Breaking Through Trauma: Ketamine-Assisted Psychotherapy for Veterans & First Responders